Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
vorinostat + vinorelbine
- Development stage
- Unknown
- Lead developer
- Merck
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Vorinostat + vinorelbine is a combination of two chemotherapeutic agents used in oncology research and clinical trials. Vorinostat is a histone deacetylase (HDAC) inhibitor that works by inhibiting the enzymatic activity of HDAC1, HDAC2, HDAC3 (Class I), and HDAC6 (Class II), leading to increased acetylation of histones and other proteins. This results in altered gene expression, cell cycle arrest, apoptosis, inhibition of angiogenesis, and downregulation of immunosuppressive interleukins[4][5][6]. Vinorelbine is a semi-synthetic vinca alkaloid that acts as an antimicrotubule agent by binding to tubulin beta chain and inhibiting microtubule polymerization. This disrupts mitotic spindle formation during cell division, causing metaphase arrest and subsequent apoptosis in proliferating cancer cells[1][8]. The combination has been investigated for synergistic effects in various malignancies.
- Brand names
- ZolinzaNavelbine
- Other names
- suberoylanilide hydroxamic acidSAHA
02
Targets
HDAC6 (Histone deacetylase 6)HDAC1 (Histone Deacetylase 1)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on vorinostat + vinorelbine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on vorinostat + vinorelbine.